Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estimating impossible curves using NONMEM

R C Schoemaker1, A F Cohen

  • 1Centre for Human Drug Research, Leiden, The Netherlands. rs@chdr.LeidenUniv.nl

British Journal of Clinical Pharmacology
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using machine learning techniques to characterize sleep-deprived driving behavior.

Traffic injury prevention·2021
Same author

Towards remote monitoring in pediatric care and clinical trials-Tolerability, repeatability and reference values of candidate digital endpoints derived from physical activity, heart rate and sleep in healthy children.

PloS one·2021
Same author

The use of machine learning improves the assessment of drug-induced driving behaviour.

Accident; analysis and prevention·2020
Same author

Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.

Pharmacological reviews·2020
Same author

Correction to: Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019
Same author

Retinal oximetry and fractal analysis of capillary maps in sickle cell disease patients and matched healthy volunteers.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2019
Same journal

ACEi/ARB in adults older than 85 years after AKI: Beyond single-drug paradigm to phenotype-guided care.

British journal of clinical pharmacology·2026
Same journal

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway.

British journal of clinical pharmacology·2026
Same journal

Predicting cognitive function in Alzheimer's clinical trials via amyloid β-protein biomarkers.

British journal of clinical pharmacology·2026
Same journal

Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study.

British journal of clinical pharmacology·2026
Same journal

Congenital malformations and medication exposures: Lack of data or lack of concern?

British journal of clinical pharmacology·2026
Same journal

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients.

British journal of clinical pharmacology·2026
See all related articles

Nonlinear mixed-effects modeling integrates data from multiple subjects to improve pharmacokinetic parameter estimation when individual data is insufficient. This approach enhances understanding of drug behavior, especially in complex scenarios like low-dose studies or when combining pharmacokinetics and pharmacodynamics.

Area of Science:

  • Pharmacometrics
  • Pharmacokinetics
  • Pharmacodynamics

Background:

  • Individual subject data may lack sufficient information for accurate pharmacokinetic parameter estimation.
  • Complex models or incomplete data across subjects can hinder model fitting.
  • Nonlinear mixed-effects modeling (NLME) offers a solution by integrating information across subjects.

Purpose of the Study:

  • To illustrate the application and benefits of nonlinear mixed-effects modeling in pharmacokinetic studies.
  • To demonstrate NLME's utility when individual data is sparse or assay limitations exist.
  • To showcase NLME for simultaneous pharmacokinetic and pharmacodynamic modeling.

Main Methods:

  • Application of nonlinear mixed-effects modeling (NLME).
  • Analysis of pharmacokinetic data from rising dose studies.

Related Experiment Videos

  • Modeling of enoxaparin (Clexane) and dalteparin (Fragmin) kinetics and dynamics.
  • Utilizing anti-Xa activity for low molecular weight heparin analysis.

    • Main Results:

    • NLME successfully improved parameter estimates in scenarios with limited individual data (e.g., low doses).
    • The methodology effectively handled assay limitations and residual low-level activity.
    • Simultaneous pharmacokinetic and pharmacodynamic modeling was achieved for dalteparin.

    Conclusions:

    • Nonlinear mixed-effects modeling is a powerful tool for enhancing pharmacokinetic and pharmacodynamic analyses.
    • NLME provides robust parameter estimates even with incomplete or sparse data.
    • This approach is valuable for complex drug development studies, including those with low molecular weight heparins.